Menu
Search
|

Menu

Close
X

Infinity Pharmaceuticals Inc INFI.OQ (NASDAQ Stock Exchange Global Select Market)

1.91 USD
-0.07 (-3.54%)
As of Jul 20
chart
Previous Close 1.98
Open 1.99
Volume 41,169
3m Avg Volume 95,146
Today’s High 2.00
Today’s Low 1.89
52 Week High 3.75
52 Week Low 0.93
Shares Outstanding (mil) 56.07
Market Capitalization (mil) 111.02
Forward P/E 2.87
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.25 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
6
FY16
19
FY15
109
EPS (USD)
FY18
-0.182
FY17
0.640
FY16
-0.603
FY15
-2.648
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
2.87
33.34
Price to Sales (TTM)
vs sector
18.50
8.11
Price to Book (MRQ)
vs sector
2.26
4.23
Price to Cash Flow (TTM)
vs sector
3.20
22.22
Total Debt to Equity (MRQ)
vs sector
0.00
17.18
LT Debt to Equity (MRQ)
vs sector
0.00
13.08
Return on Investment (TTM)
vs sector
48.61
13.18
Return on Equity (TTM)
vs sector
56.47
15.09

EXECUTIVE LEADERSHIP

Adelene Perkins
Chairman of the Board, Chief Executive Officer, Since 2017
Salary: $568,500.00
Bonus: $369,525.00
Lawrence Bloch
President, Principal Financial Officer, Principal Accounting Officer, Since 2016
Salary: $390,000.00
Bonus: $156,000.00
William Bertrand
Executive Vice President, General Counsel, Since 2015
Salary: --
Bonus: --
Melissa Hackel
Vice President - Finance, Since 2017
Salary: --
Bonus: --
Joseph Pearlberg
Vice President - Clinical Development, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

784 Memorial Dr
CAMBRIDGE   MA   02139-4613

Phone: +1617.4531000
Site: www.infi.com

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.

SPONSORED STORIES